Speakers - 2026

Title: Medical Cannabis for the Management of Migraine Pain in Adults

Abstract

Migraines are a chronic neurological disorder characterized by recurrent, unilateral headaches associated with nausea, photophobia and neurological symptoms.  While multiple treatment options exist, many individuals continue to experience poor symptom control or treatment-related side effects. There has growing interest in medical cannabis as a therapeutic option, because of its effects on the endocannabinoid system, which plays a role in regulating pain and inflammation. 

Aim:

To assess the effectiveness, underlying mechanisms, and safety of medical cannabis in the treatment of migraine pain in adults.

Methods:

A literature review was performed, including systematic reviews, observational data, and clinical studies focused on the use of cannabis-based treatments in migraine care. Relevant publications were identified through academic databases and evaluated for outcomes relating to migraine frequency, severity, and associated symptoms.

Results:

Research findings suggest that key cannabinoids, including THC and CBD, are associated with reductions in migraine occurrence and severity. These effects are thought to result from reduced CGRP secretion and decreased vasodilation within cerebral vessels. Multiple studies show improvements in migraine frequency and related symptoms such as nausea and vomiting, with some evidence suggesting a 51% greater reduction than conventional treatments. However, it does carries potential risks, including medication overuse headache, tolerance, dependency, and neuropsychiatric complications, especially in high-risk groups.

Conclusion:

Cannabis-based therapies show potential as an option for individuals with treatment-resistant migraine. However, current research is limited due to variability in study designs and insufficient long-term safety data. Further large-scale randomized controlled trials are needed to confirm its effectiveness, safety, and place in clinical practice.